Trial Information

Summary: Evaluation of single-doses of acute migraine medication versus placebo - administered one time, subcutaneously

A study to evaluate the effectiveness of three different doses of Tezampanel vs. placebo in a single episode of migraine. You will receive a one-time subcutaneous injection of medication and then record your migraine response in a diary while being observed at our clinic. Your chances of receiving the new medication is 3 out of 4 and your chance of receiving placebo is 1 out of 4. A total of 3 study visits.

Patient Inclusion Criteria

• 18-65 years old
• history of 1-6 acute migraine headaches per month
• not using any daily preventative medications for 14 days before study screening visit

Patient Exclusion Criteria

• cardiovascular illness
• high blood pressure

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:31:39 AM